Phase 2

Oncology·MeSH: Neoplasm Metastasis

14 drugs in development·14 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
bexobrutideg	Nurix Therapeutics, Inc. (NRIX)
surzebiclimab	BeOne Medicines Ltd. (ONC)

Phase 2(8)

Drug	Company
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
CX-2029	CytomX Therapeutics, Inc. (CTMX)
Elraglusib Oral Tablet	ACTUATE THERAPEUTICS, INC. (ACTU)
Evalstotug (BA3071)	BioAtla, Inc. (BCAB)
INS1148	INSMED Inc (INSM)
intranasal epinephrine technology product candidates	ARS Pharmaceuticals, Inc. (SPRY)
SER-287	Seres Therapeutics, Inc. (MCRB)
tnx-4800	Tonix Pharmaceuticals Holding Corp. (TNXP)

Phase 1(1)

Drug	Company
APG333	Apogee Therapeutics, Inc. (APGE)

Unknown(2)

Drug	Company
laromestrocel	Longeveron Inc. (LGVN)
null	LUMOS PHARMA, INC. (NLNK)

Phase 2/Phase 3(1)

Drug	Company
CA-170	CURIS INC (CRIS)

BioSniper tracks 14 drugs in development for Phase 2 across 14 companies.

There are 1 clinical trial targeting Phase 2 tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.